# Puma Biotechnology, Inc. clinical trials: 38 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials with Puma Biotechnology, Inc. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Puma Biotechnology, Inc.: 38 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/puma-biotechnology-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 12, 2026 | NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Puma Biotechnology, Inc. | Phase 2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465757) |
| April 16, 2024 | NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Puma Biotechnology, Inc. | Phase 2 | Recruiting | Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06369285) |
| October 23, 2023 | NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Puma Biotechnology, Inc. | Phase 2 | Recruiting | Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06095505) |
| April 29, 2020 | NCT04366713 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | Puma Biotechnology, Inc. | Phase 2 | Completed | HER2 Amplified Breast Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04366713) |
| December 24, 2018 | NCT03786107 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib | Puma Biotechnology, Inc. | Observational | Terminated | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer | 1,583 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03786107) |
| March 27, 2015 | NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With... | Puma Biotechnology, Inc. | Phase 2 | Completed | Early Stage HER2+ Breast Cancer | 563 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02400476) |
| January 8, 2015 | NCT02334501 | Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects | Puma Biotechnology, Inc. | Phase 1 | Completed | Healthy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02334501) |
| October 1, 2013 | NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Puma Biotechnology, Inc. | Phase 2 | Terminated | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | 582 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01953926) |
| April 9, 2013 | NCT01827267 | Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | Puma Biotechnology, Inc. | Phase 2 | Completed | HER2-mutant Non-Small Cell Lung Cancer | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01827267) |
| March 11, 2013 | NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received... | Puma Biotechnology, Inc. | Phase 3 | Completed | HER2+ Metastatic Breast Cancer (MBC) | 621 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01808573) |
| June 11, 2010 | NCT01142063 | A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects | Puma Biotechnology, Inc. | Observational | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01142063) |
| May 24, 2010 | NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | Puma Biotechnology, Inc. | Phase 1 | Completed | Advanced Malignant Solid Tumors | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01128842) |
| April 28, 2010 | NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | Puma Biotechnology, Inc. | Phase 1/2 | Completed | Breast Cancer | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01111825) |
| August 13, 2009 | NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | Puma Biotechnology, Inc. | Phase 1 | Completed | Advanced Malignant Solid Tumors | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00958724) |
| July 3, 2009 | NCT00932464 | Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib | Puma Biotechnology, Inc. | Phase 1 | Withdrawn | Healthy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00932464) |
| June 5, 2009 | NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | Puma Biotechnology, Inc. | Phase 2 | Completed | Breast Cancer | 479 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00915018) |
| April 9, 2009 | NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | Puma Biotechnology, Inc. | Phase 3 | Completed | Breast Cancer | 2,840 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00878709) |
| March 18, 2009 | NCT00864487 | Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib | Puma Biotechnology, Inc. | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00864487) |
| March 12, 2009 | NCT00860223 | Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin | Puma Biotechnology, Inc. | Phase 1 | Completed | Healthy | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00860223) |
| February 6, 2009 | NCT00838539 | Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors | Puma Biotechnology, Inc. | Phase 1 | Completed | Neoplasms, Malignant Carcinoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00838539) |
| December 23, 2008 | NCT00814060 | Study Evaluating TwoTablet Formulations of Neratinib (HKI-272) | Puma Biotechnology, Inc. | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00814060) |
| October 29, 2008 | NCT00781430 | Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease | Puma Biotechnology, Inc. | Phase 1 | Completed | Hepatic Insufficiency | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00781430) |
| October 22, 2008 | NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | Puma Biotechnology, Inc. | Phase 2 | Completed | Advanced Breast Cancer, Breast Cancer | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00777101) |
| October 8, 2008 | NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | Puma Biotechnology, Inc. | Phase 1 | Completed | Advanced Malignant Solid Tumors | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00768469) |
| September 23, 2008 | NCT00757809 | Study Evaluating The Tolerability Of Multiple Doses Of HKI-272 | Puma Biotechnology, Inc. | Phase 1 | Completed | Healthy Subjects | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00757809) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 5 |
| Phase 2 | 11 |
| Phase 3 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 32 |
| Recruiting | 3 |
| Terminated | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 15 |
| Neoplasms | 6 |
| Neoplasm Metastasis | 4 |
| Lung Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Small Cell Lung Carcinoma | 2 |
| Uterine Cervical Neoplasms | 1 |
| Hepatic Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Freight and cargo companies in the United States](https://specstream.ai/data/businesses/freight-and-cargo-companies/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [Architectural design firms in the United States](https://specstream.ai/data/businesses/architectural-design-firms/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
